drugset / Trial / NCT03873493
A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to evaluate the efficacy of the combination of venetoclax plus ibrutinib for treating adults with T-cell prolymphocytic leukemia (T-PLL).
Timeline
- Start
- 2020-01-14
- Primary completion
- 2021-11-04
- Completion
- 2021-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 420 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |